Martinez, Subiela SilviaHorvatic, AnitaEscribano, DamianPardo, Luis MarinMrljak, VladimirBurchmore, RichardCeron, Jose J.2022-12-232022-12-232017-08-08Martinize, S. S. vd. (2017). ''Identification of novel biomarkers for treatment monitoring in canine leishmaniosis by high-resolution quantitative proteomic analysis''. Veterinary Immunology and Immunopathology, 191, 60-67.https://www.sciencedirect.com/science/article/pii/S01652427173015750165-2427https://doi.org/10.1016/j.vetimm.2017.08.0041873-2534http://hdl.handle.net/11452/30065The objective of this study was to use the Tandem Mass Tag (TMT) isobaric label-based proteomic approach, in order to identify new potential biomarkers for the treatment monitoring of canine leishmaniosis that could not be identified by the use of gel-based techniques. For this purpose serum samples were obtained from 5 clinically diseased dogs before and one month after the treatment of canine leishmaniosis. The non-depleted serum samples were subjected to reduction, alkylation and trypsin digestion, and the resulting peptides were labeled using 6-plex TMT reagents. To obtain information about protein identities and relative quantification, liquid chromatography-MS analysis of multiplexed TMT-labeled peptides was employed. This gel-free, label-based quantitative proteomic approach enabled identification of 117 canine proteins. Among these, 23 showed significant difference (p < 0.05) in expression (two downregulated and 21 upregulated ranging from 1.25 to 2.5 fold change). Comparison of gel-free TMT-based quantification and a gel-based approach previously applied to the same samples resulted in the identification of some common markers (Apo-A1, vitamin D binding protein and RBP4). However, 20 additional differentially represented proteins were highlighted by the gel-free approach, 13 of which have not been previously reported in canine leishmaniosis. In conclusion, the TMT-based proteomic approach allowed identification of new serum proteins that significantly change in concentration after canine leishmaniosis treatment. These proteins are involved in various physiopathological processes such as inflammatory, coagulation or defense mechanisms, and could potentially be suitable biomarkers for treatment monitoring of this parasitic disease.eninfo:eu-repo/semantics/closedAccessImmunologyVeterinary sciencesBiomarkersDogGel free proteomicsLeishmaniosisTreatmentAlpha-trypsin inhibitorMass-spectrometryMembrane-proteinsKinin systemPlasmaDogsComplexPromastigotesInflammationDiseaseAcute-phase proteinsAllopurinolAnimalsAntiprotozoal agentsBiomarkersDog diseasesDogsFemaleFerritinsLeishmaniasisMaleMeglumineOrganometallic compoundsProteomicsSerum globulinsArticle0004122541000092-s2.0-85028374669606719128895868ImmunologyVeterinary sciencesLeishmania Infantum; Dog; PsychodidaeAllopurinolApolipoprotein A1Beta 2 glycoprotein 1 precursorBeta2 glycoprotein 1Biological markerFibronectinFibronectin isoform X1Inter alpha trypsin inhibitorInter alpha trypsin inhibitor heavy chain H1 isoform X1Inter alpha trypsin inhibitor heavy chain H2Inter alpha trypsin inhibitor heavy chain H4 isoform X1Kininogen 1 isoform X1Kininogen 1 isoform X2Mmyosin VIPlasminogenPlasminogen precursorRetinol binding protein 4SerotransferrinSerum albuminSerum albumin isoform X1Serum albumin precursorSpectrinSpectrin beta chain erythrocyticSpectrin beta chain non erythrocytic 1 isoform X1TransferrinTrypsinUunclassified drugUunconventional myosin VI isoform X1Unindexed drugVitamin D binding proteinAcute phase proteinAllopurinolAntiprotozoal agentBiological markerFerritinMeglumineMeglumine antimoniateOrganometallic compoundSerum globulinAlkylationAnimal experimentArticleBlood samplingComparative studyDog diseaseDown regulationDrug monitoringEnzyme metabolismFemaleGene expression profilingGene ontologyLeishmaniasisLiquid chromatography-mass spectrometryMaleNonhumanProtein analysisProtein expressionProtein foldingProteomicsQuantitative analysisUpregulationAnimalBloodDogDog diseaseLeishmaniasisMetabolismParasitologyProceduresProteomicsVeterinary